(E)-phenyl- and -heteroaryl-substituted 0-benzoyl- (or acyl)oximes as lipoprotein-associated phospholipase A2 inhibitors

被引：26

作者：

Jeong, TS

Kim, MJ

Yu, H

Kim, KS

Choi, JK

Kim, SS

Lee, WS ^{[1
]}

机构：

[1] Korea Res Inst Biosci & Biotechnol, Natl Res Lab Lipid Metab & Atherosclerosis, Taejon 305333, South Korea

[2] Korea Res Inst Chem Technol, Taejon 305600, South Korea

来源：

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS | 2005年 / 15卷 / 05期

基金：

新加坡国家研究基金会;

关键词：

Lp-PLA2; inhibitor;

D O I：

10.1016/j.bmcl.2004.11.063

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of (E)-phenyl- and -heteroaryl- substituted O-benzoyl-(or acyl)oximes 3a-n were synthesized for evaluating their human lipoprotein-associated phospholiphase A(2) (Lp-PLA(2)) inhibitory activities. The less lipophilic derivatives 3a-c showed the most potent in vitro inhibitory activity on human Lp-PLA2. (c) 2004 Elsevier Ltd. All rights reserved.

引用

收藏

页码：1525 / 1527

页数：3

相关论文

共 18 条

[1] Low-density lipoprotein-antioxidant constituents of Saururus chinensis [J].

Ahn, BT ;

Lee, S ;

Lee, SB ;

Lee, ES ;

Kim, JG ;

Bok, SH ;

Jeong, TS .

JOURNAL OF NATURAL PRODUCTS, 2001, 64 (12) :1562-1564

[2] 1-(Arylpiperazinylamidoalkyl)-pyrimidones:: Orally active inhibitors of lipoprotein-associated phospholipase A2 [J].

Bloomer, JC ;

Boyd, HF ;

Hickey, DMB ;

Ife, RJ ;

Leach, CA ;

Macphee, CH ;

Milliner, KJ ;

Pinto, IL ;

Rawlings, DA ;

Smith, SA ;

Stansfield, IG ;

Stanway, SJ ;

Taylor, MA ;

Theobald, CJ ;

Whittaker, CM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2001, 11 (14) :1925-1929

[3] 2-(Alkylthio)pyrimidin-4-ones as novel, reversible inhibitors of lipoprotein-associated phospholipase A2 [J].

Boyd, HF ;

Flynn, ST ;

Hickey, DMB ;

Ife, RJ ;

Jones, M ;

Leach, CA ;

Macphee, CH ;

Milliner, KJ ;

Rawlings, DA ;

Slingsby, BP ;

Smith, SA ;

Stansfield, IG ;

Tew, DG ;

Theobald, CJ .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (04) :395-398

[4] N-1 substituted pyrimidin-4-ones:: Novel, orally active inhibitors of lipoprotein-associated phospholipase A2 [J].

Boyd, HF ;

Fell, SCM ;

Flynn, ST ;

Hickey, DMB ;

Ife, RJ ;

Leach, CA ;

Macphee, CH ;

Milliner, KJ ;

Moores, KE ;

Pinto, IL ;

Porter, RA ;

Rawlings, DA ;

Smith, SA ;

Stansfield, IG ;

Tew, DG ;

Theobald, CJ ;

Whittaker, CM .

BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2000, 10 (22) :2557-2561

[5] SB-253514 and analogues:: Novel inhibitors of lipoprotein associated phospholipase A2 produced by Pseudomonas fluorescens DSM 11579 -: II.: Physico-chemical properties and structure elucidation [J].

Busby, DJ ;

Copley, RCB ;

Hueso, JA ;

Readshaw, SA ;

Rivera, A .

JOURNAL OF ANTIBIOTICS, 2000, 53 (07) :670-676

[6] Lipoprotein-associated phospholipase A2, platelet-activating factor acetylhydrolase:: a potential new risk factor for coronary artery disease [J].

Caslake, MJ ;

Packard, CJ ;

Suckling, KE ;

Holmes, SD ;

Chamberlain, P ;

Macphee, CH .

ATHEROSCLEROSIS, 2000, 150 (02) :413-419

[7]

CHAPMAN MJ, 1981, J LIPID RES, V22, P399

[8] Elimination reactions of (E)- and (Z)-benzaldehyde O-benzoyloximes.: Transition state differences for the syn- and anti-eliminations forming nitriles [J].

Cho, BR ;

Chung, HS ;

Cho, NS .

JOURNAL OF ORGANIC CHEMISTRY, 1998, 63 (14) :4685-4690

[9] DISTRIBUTION AND CHEMICAL COMPOSITION OF ULTRACENTRIFUGALLY SEPARATED LIPOPROTEINS IN HUMAN SERUM [J].

HAVEL, RJ ;

EDER, HA ;

BRAGDON, JH .

JOURNAL OF CLINICAL INVESTIGATION, 1955, 34 (09) :1345-1353

[10] Lipoprotein-associated PLA2 inhibition -: a novel, non-lipid lowering strategy for atherosclerosis therapy [J].

Leach, CA ;

Hickey, DMB ;

Ife, RJ ;

Macphee, CH ;

Smith, SA ;

Tew, DG .

FARMACO, 2001, 56 (1-2) :45-50